Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 181 to 186 of 186 entries
Sorted by: Best Match Show Resources per page
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, Pazdur R, Lemery SJ.
PMID: 34083238
Clin Cancer Res. 2021 Sep 01;27(17):4685-4689. doi: 10.1158/1078-0432.CCR-21-0327. Epub 2021 Jun 03.

The FDA approved pembrolizumab on June 16, 2020, for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high [TMB-H; ≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following...

Cite
Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021;27(17):4685-4689doi: 10.1158/1078-0432.CCR-21-0327.
Marcus, L., Fashoyin-Aje, L. A., Donoghue, M., Yuan, M., Rodriguez, L., Gallagher, P. S., Philip, R., Ghosh, S., Theoret, M. R., Beaver, J. A., Pazdur, R., & Lemery, S. J. (2021). FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(17), 4685-4689. https://doi.org/10.1158/1078-0432.CCR-21-0327
Marcus, Leigh, et al. "FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,17 (2021): 4685-4689. doi: https://doi.org/10.1158/1078-0432.CCR-21-0327
Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, Pazdur R, Lemery SJ. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021 Sep 01;27(17):4685-4689. doi: 10.1158/1078-0432.CCR-21-0327. Epub 2021 Jun 03. PMID: 34083238; PMCID: PMC8416776.
Copy Download .nbib Format: NLM
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Chang E, Weinstock C, Zhang L, Fiero MH, Zhao M, Zahalka E, Ricks TK, Fourie Zirkelbach J, Qiu J, Yu J, Chen XH, Bhatnagar V, Goldberg KB, Tang S, Kluetz PG, Pazdur R, Ibrahim A, Beaver JA, Amiri-Kordestani L.
PMID: 34417198
Clin Cancer Res. 2021 Aug 20; doi: 10.1158/1078-0432.CCR-21-2334. Epub 2021 Aug 20.

On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study,...

Cite
Chang E, Weinstock C, Zhang L, et al. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-2334.
Chang, E., Weinstock, C., Zhang, L., Fiero, M. H., Zhao, M., Zahalka, E., Ricks, T. K., Fourie Zirkelbach, J., Qiu, J., Yu, J., Chen, X. H., Bhatnagar, V., Goldberg, K. B., Tang, S., Kluetz, P. G., Pazdur, R., Ibrahim, A., Beaver, J. A., & Amiri-Kordestani, L. (2021). FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-2334
Chang, Elaine, et al. "FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-2334
Chang E, Weinstock C, Zhang L, Fiero MH, Zhao M, Zahalka E, Ricks TK, Fourie Zirkelbach J, Qiu J, Yu J, Chen XH, Bhatnagar V, Goldberg KB, Tang S, Kluetz PG, Pazdur R, Ibrahim A, Beaver JA, Amiri-Kordestani L. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma. Clin Cancer Res. 2021 Aug 20; doi: 10.1158/1078-0432.CCR-21-2334. Epub 2021 Aug 20. PMID: 34417198.
Copy Download .nbib Format: NLM
Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer.

Cancer

Murugappan MN, King-Kallimanis BL, Mangir C, Howie L, Bhatnagar V, Beaver JA, Basch EM, Henson SR, Kluetz PG.
PMID: 34634139
Cancer. 2021 Oct 11; doi: 10.1002/cncr.33959. Epub 2021 Oct 11.

BACKGROUND: The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 Physical Functioning subscale is a widely used patient-reported outcome measure that quantifies cancer patients' physical functioning. Strong floor/ceiling effects can affect a...

Cite
Murugappan MN, King-Kallimanis BL, Mangir C, et al. Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer. Cancer. 2021;doi: 10.1002/cncr.33959.
Murugappan, M. N., King-Kallimanis, B. L., Mangir, C., Howie, L., Bhatnagar, V., Beaver, J. A., Basch, E. M., Henson, S. R., & Kluetz, P. G. (2021). Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer. Cancer, . https://doi.org/10.1002/cncr.33959
Murugappan, Meena N, et al. "Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33959
Murugappan MN, King-Kallimanis BL, Mangir C, Howie L, Bhatnagar V, Beaver JA, Basch EM, Henson SR, Kluetz PG. Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer. Cancer. 2021 Oct 11; doi: 10.1002/cncr.33959. Epub 2021 Oct 11. PMID: 34634139.
Copy Download .nbib Format: NLM
Impact of COVID-19 pandemic on ophthalmology medical student teaching: educational innovations, challenges, and future directions.

Survey of ophthalmology

Succar T, Beaver HA, Lee AG.
PMID: 33838164
Surv Ophthalmol. 2022 Jan-Feb;67(1):217-225. doi: 10.1016/j.survophthal.2021.03.011. Epub 2021 Apr 07.

Graduate medical education (GME) in ophthalmology has faced and overcome many challenges over the past years, and 2020 has been a game-changer. Although the severe acute respiratory syndrome coronavirus pandemic disrupted medical education globally, ophthalmic educators rapidly transformed their...

Cite
Succar T, Beaver HA, Lee AG. Impact of COVID-19 pandemic on ophthalmology medical student teaching: educational innovations, challenges, and future directions. Surv Ophthalmol. 2021;67(1):217-225doi: 10.1016/j.survophthal.2021.03.011.
Succar, T., Beaver, H. A., & Lee, A. G. (2022). Impact of COVID-19 pandemic on ophthalmology medical student teaching: educational innovations, challenges, and future directions. Survey of ophthalmology, 67(1), 217-225. https://doi.org/10.1016/j.survophthal.2021.03.011
Succar, Tony, et al. "Impact of COVID-19 pandemic on ophthalmology medical student teaching: educational innovations, challenges, and future directions." Survey of ophthalmology vol. 67,1 (2022): 217-225. doi: https://doi.org/10.1016/j.survophthal.2021.03.011
Succar T, Beaver HA, Lee AG. Impact of COVID-19 pandemic on ophthalmology medical student teaching: educational innovations, challenges, and future directions. Surv Ophthalmol. 2022 Jan-Feb;67(1):217-225. doi: 10.1016/j.survophthal.2021.03.011. Epub 2021 Apr 07. PMID: 33838164.
Copy Download .nbib Format: NLM
Commentary: The devil is in the details.

JTCVS techniques

Falasa MP, Beaver TM.
PMID: 34401806
JTCVS Tech. 2021 Mar 26;8:43. doi: 10.1016/j.xjtc.2021.03.023. eCollection 2021 Aug.

No abstract available.

Cite
Falasa MP, Beaver TM. Commentary: The devil is in the details. JTCVS Tech. 2021;8:43doi: 10.1016/j.xjtc.2021.03.023.
Falasa, M. P., & Beaver, T. M. (2021). Commentary: The devil is in the details. JTCVS techniques, 843. https://doi.org/10.1016/j.xjtc.2021.03.023
Falasa, Matheus P, and Beaver, Thomas M. "Commentary: The devil is in the details." JTCVS techniques vol. 8 (2021): 43. doi: https://doi.org/10.1016/j.xjtc.2021.03.023
Falasa MP, Beaver TM. Commentary: The devil is in the details. JTCVS Tech. 2021 Mar 26;8:43. doi: 10.1016/j.xjtc.2021.03.023. eCollection 2021 Aug. PMID: 34401806; PMCID: PMC8350754.
Copy Download .nbib Format: NLM
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.

Clinical cancer research : an official journal of the American Association for Cancer Research

Koch AL, Vellanki PJ, Drezner N, Li X, Mishra-Kalyani PS, Shen YL, Xia H, Li Y, Liu J, Zirkelbach JF, Palazov E, Gamarian A, Choo Q, Girčys A, Rohr UP, Fesenko N, Spillman D, Pazdur R, Beaver JA, Singh H.
PMID: 34301748
Clin Cancer Res. 2021 Dec 15;27(24):6638-6643. doi: 10.1158/1078-0432.CCR-21-1034. Epub 2021 Jul 22.

On December 18, 2020, the FDA approved osimertinib as adjuvant therapy in patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. The approval...

Cite
Koch AL, Vellanki PJ, Drezner N, et al. FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clin Cancer Res. 2021;27(24):6638-6643doi: 10.1158/1078-0432.CCR-21-1034.
Koch, A. L., Vellanki, P. J., Drezner, N., Li, X., Mishra-Kalyani, P. S., Shen, Y. L., Xia, H., Li, Y., Liu, J., Zirkelbach, J. F., Palazov, E., Gamarian, A., Choo, Q., Girčys, A., Rohr, U. P., Fesenko, N., Spillman, D., Pazdur, R., Beaver, J. A., & Singh, H. (2021). FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6638-6643. https://doi.org/10.1158/1078-0432.CCR-21-1034
Koch, Abigail L, et al. "FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6638-6643. doi: https://doi.org/10.1158/1078-0432.CCR-21-1034
Koch AL, Vellanki PJ, Drezner N, Li X, Mishra-Kalyani PS, Shen YL, Xia H, Li Y, Liu J, Zirkelbach JF, Palazov E, Gamarian A, Choo Q, Girčys A, Rohr UP, Fesenko N, Spillman D, Pazdur R, Beaver JA, Singh H. FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clin Cancer Res. 2021 Dec 15;27(24):6638-6643. doi: 10.1158/1078-0432.CCR-21-1034. Epub 2021 Jul 22. PMID: 34301748.
Copy Download .nbib Format: NLM
Showing 181 to 186 of 186 entries